This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2015 Jan 22;372(4):374-5.

doi: 10.1056/NEJMe1413488. Epub 2014 Dec 6.

Release the hounds! Activating the T-cell response to cancer

Mario Sznol¹, Dan L Longo

Affiliations

PMID: 25482238
DOI: 10.1056/NEJMe1413488

Editorial

Release the hounds! Activating the T-cell response to cancer

Mario Sznol et al. N Engl J Med. 2015.

. 2015 Jan 22;372(4):374-5.

doi: 10.1056/NEJMe1413488. Epub 2014 Dec 6.

Authors

Mario Sznol¹, Dan L Longo

Affiliation

¹ From the Section of Medical Oncology, Yale University School of Medicine, New Haven, CT (M.S.).

PMID: 25482238
DOI: 10.1056/NEJMe1413488

No abstract available

PubMed Disclaimer

Comment on

Nivolumab in previously untreated melanoma without BRAF mutation.
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. Robert C, et al. N Engl J Med. 2015 Jan 22;372(4):320-30. doi: 10.1056/NEJMoa1412082. Epub 2014 Nov 16. N Engl J Med. 2015. PMID: 25399552 Clinical Trial.
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. Ansell SM, et al. N Engl J Med. 2015 Jan 22;372(4):311-9. doi: 10.1056/NEJMoa1411087. Epub 2014 Dec 6. N Engl J Med. 2015. PMID: 25482239 Free PMC article. Clinical Trial.

Similar articles

Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.
Villasboas JC, Ansell SM. Villasboas JC, et al. Expert Rev Anticancer Ther. 2016;16(1):5-12. doi: 10.1586/14737140.2016.1121812. Epub 2015 Dec 7. Expert Rev Anticancer Ther. 2016. PMID: 26577822 Review.
Immunotherapy for melanoma using programmed death 1 checkpoint inhibitors.
Hamid O. Hamid O. Clin Adv Hematol Oncol. 2014 Nov;12(11):782-4. Clin Adv Hematol Oncol. 2014. PMID: 25674719 Review. No abstract available.
Nivolumab shows clinical activity in Hodgkin's lymphoma.
Bagcchi S. Bagcchi S. Lancet Oncol. 2015 Mar;16(3):e108. doi: 10.1016/S1470-2045(15)70024-0. Epub 2015 Jan 30. Lancet Oncol. 2015. PMID: 25639369 No abstract available.
Haematological cancer: PD-1 blockade: opening the door to attack.
Hutchinson L. Hutchinson L. Nat Rev Clin Oncol. 2015 Feb;12(2):65. doi: 10.1038/nrclinonc.2014.227. Epub 2014 Dec 23. Nat Rev Clin Oncol. 2015. PMID: 25533946 No abstract available.
Skin cancer. Golden age of melanoma therapy.
Hutchinson L. Hutchinson L. Nat Rev Clin Oncol. 2015 Jan;12(1):1. doi: 10.1038/nrclinonc.2014.219. Epub 2014 Dec 16. Nat Rev Clin Oncol. 2015. PMID: 25511188 No abstract available.

See all similar articles

Cited by

Meta-Analysis of Quality of Life in Cancer Patients Treated With Immune Checkpoint Inhibitors.
Gonzalez BD, Eisel SL, Bowles KE, Hoogland AI, James BW, Small BJ, Sharpe S, Hyland KA, Bulls HW, Christy SM, Mansfield J, Nelson AM, Alla R, Maharaj K, Kennedy B, Lafranchise E, Williams NL, Jennewein S, Oswald LB, Postow MA, Dicker AP, Jim HSL. Gonzalez BD, et al. J Natl Cancer Inst. 2022 Jun 13;114(6):808-818. doi: 10.1093/jnci/djab171. J Natl Cancer Inst. 2022. PMID: 34508604 Free PMC article.
Current status and future directions of cancer immunotherapy.
Zhang H, Chen J. Zhang H, et al. J Cancer. 2018 Apr 19;9(10):1773-1781. doi: 10.7150/jca.24577. eCollection 2018. J Cancer. 2018. PMID: 29805703 Free PMC article. Review.
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.
Charych D, Khalili S, Dixit V, Kirk P, Chang T, Langowski J, Rubas W, Doberstein SK, Eldon M, Hoch U, Zalevsky J. Charych D, et al. PLoS One. 2017 Jul 5;12(7):e0179431. doi: 10.1371/journal.pone.0179431. eCollection 2017. PLoS One. 2017. PMID: 28678791 Free PMC article.
Immune Checkpoint in Glioblastoma: Promising and Challenging.
Huang J, Liu F, Liu Z, Tang H, Wu H, Gong Q, Chen J. Huang J, et al. Front Pharmacol. 2017 May 9;8:242. doi: 10.3389/fphar.2017.00242. eCollection 2017. Front Pharmacol. 2017. PMID: 28536525 Free PMC article. Review.
Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity.
Omokoko TA, Luxemburger U, Bardissi S, Simon P, Utsch M, Breitkreuz A, Türeci Ö, Sahin U. Omokoko TA, et al. J Immunol Res. 2016;2016:9540975. doi: 10.1155/2016/9540975. Epub 2016 Jan 5. J Immunol Res. 2016. PMID: 27057556 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information

-